Skip to main content
. Author manuscript; available in PMC: 2015 Apr 8.
Published in final edited form as: Sci Transl Med. 2015 Mar 18;7(279):279ra37. doi: 10.1126/scitranslmed.3010370

Figure 6.

Figure 6

Estimated reduction in transmissibility of DENV (quantified by serotype specific R0) caused by wMel infection. Median posterior estimates and 95% credible intervals are shown. ‘Baseline’ scenario: assumes data on infectious saliva translates directly to human infectiousness. ‘Higher/Lower dose’ scenarios: assume 10-fold higher/lower infectious dose for mosquito-to-human transmission than estimated using saliva infection model. ‘Average dose’: assumes same infectious dose for all serotypes (average across serotypes) for mosquito-to-human transmission. ‘Same viral profile’: uses a model of human viral kinetics that is the same for all serotypes. ‘Alternative model’: uses the alternative saliva infection model where wMel infection affects only the EIP.